Related Experiment Video
Updated: Mar 28, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
Jarushka Naidoo1, Alexander Drilon2
1Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract:
KRAS-mutant lung cancers account for approximately 25% of non-small cell lung carcinomas, thus representing an enormous burden of cancer worldwide. KRAS mutations are clear drivers of tumor growth and are characterized by a complex biology involving the interaction between mutant KRAS, various growth factor pathways, and tumor suppressor genes. While KRAS mutations are classically associated with a significant smoking history, they are also identified in a substantial proportion of never-smokers. These mutations are found largely in lung adenocarcinomas with solid growth patterns and tumor-infiltrating lymphocytes. A variety of tools are available for diagnosis including Sanger sequencing, multiplex mutational hotspot profiling, and next-generation sequencing. The prognostic and predictive roles of KRAS status remain controversial. It has become increasingly clear, however, that KRAS mutations drive primary resistance to EGFR tyrosine kinase inhibition. Until recently, mutant KRAS was not thought of as a clinically-targetable driver in lung cancers. With the expansion of our knowledge regarding the biology of KRAS-mutant lung cancers and the role of MEK and PI3K/mTOR inhibition, the face of targeted therapeutics for this genomic subset of patients is slowly beginning to change.
Insights
KRAS mutations drive non-small cell lung cancer growth and resistance to therapies. Emerging research explores targeted treatments for KRAS-mutant lung adenocarcinomas, offering new hope.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS mutations are key drivers in 25% of non-small cell lung carcinomas (NSCLC).
- These mutations are linked to tumor growth, complex signaling pathways, and resistance to EGFR inhibitors.
- KRAS mutations occur in both smokers and never-smokers, predominantly in lung adenocarcinomas with solid patterns.
Purpose of the Study:
- To summarize the role of KRAS mutations in lung cancer.
- To discuss diagnostic tools and the evolving understanding of KRAS as a therapeutic target.
- To highlight the potential of novel targeted therapies.
Main Methods:
- Review of current literature on KRAS-mutant lung cancer.
- Analysis of diagnostic methodologies including Sanger sequencing and next-generation sequencing.
- Examination of biological interactions and therapeutic strategies.
Main Results:
- KRAS mutations are significant drivers of NSCLC, impacting tumor biology and treatment resistance.
- Diagnostic tools are advancing, with next-generation sequencing offering comprehensive profiling.
- KRAS is increasingly recognized as a targetable driver, with MEK and PI3K/mTOR inhibitors showing promise.
Conclusions:
- KRAS-mutant lung cancer presents a substantial clinical challenge.
- Understanding KRAS biology is crucial for developing effective targeted therapies.
- New therapeutic avenues are emerging for this specific subset of lung cancer patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:18Cancer
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:23Abnormal Proliferation
02:56Treatment Resistent Cancers